샘플 요청 목록

 카트 문의
시장보고서
상품코드
1941488

면역치료제 시장 규모, 점유율 및 동향 분석 보고서 : 약제 유형별, 적응증별, 지역별, 부문 예측(2026-2033년)

Immunotherapy Drugs Market Size, Share & Trends Analysis Report By Drug Type (Monoclonal Antibodies, Immunomodulators, Vaccine), By Indication (Cancer, Infectious Diseases, Autoimmune Diseases), By Region, And Segment Forecasts, 2026 - 2033
발행일: | 리서치사: Grand View Research | 페이지 정보: 영문 100 Pages | 배송안내 : 2-10일 (영업일 기준)

    
    
    




※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

면역치료제 시장 개요

세계의 면역치료제 시장 규모는 2025년 2,857억 3,000만 달러로 추정되며, 2033년에 6,759억 8,000만 달러에 이를 것으로 예측됩니다.

또한, 2026-2033년 11.41%의 연평균 복합 성장률(CAGR)을 나타낼 것으로 예측됩니다. 이 시장의 성장은 주로 전 세계 만성질환 발생률 증가에 의해 주도되고 있습니다.

이 시장은 암, 자가면역질환 및 염증성 질환을 포함한 만성질환의 세계적인 부담 증가와 더불어 화학요법, 방사선 치료 등 기존 치료법의 한계가 드러남에 따라 성장세를 보이고 있습니다. 이러한 제약으로 인해 표적 지향적 작용기전과 환자 예후 개선이 특징인 면역요법으로의 전환이 가속화되고 있습니다. 예를 들어, 2025년 2월 세계보건기구(WHO)가 발표한 보고서에 따르면, 2020년 암으로 인한 사망자 수는 약 1,000만 명에 달할 것으로 예상되며, 이는 전 세계 사망자 6명 중 1명에 해당합니다. 유방암은 226만 건, 폐암은 221만 건, 대장암은 193만 건, 폐암으로 인한 사망자 수는 180만 명에 달했습니다. 이 기관은 또한 연간 약 40만 건의 소아암이 발생하며, 저소득 및 중저소득 국가에서 발생하는 암 사례의 30%가 감염과 관련이 있다고 지적했습니다. 이로 인해 고급 면역치료에 대한 수요가 더욱 증가하고 있습니다.

기술 발전과 활발한 연구 활동은 면역치료제 시장 추진에 있어 매우 중요한 역할을 하고 있습니다. 특히 면역관문억제제, 단일클론항체, CAR-T 치료 등 세포치료의 면역종양학의 눈부신 발전은 암 치료의 패러다임을 바꾸어 놓았습니다. 이러한 치료법은 여러 고형암과 혈액암에서 높은 효능을 보여 임상 적응증 확대에 기여하고 있습니다. 제약기업과 바이오기업들은 치료 효과 향상, 부작용 감소, 차세대 면역치료제 개발을 위해 연구개발에 많은 투자를 하고 있습니다. 전략적 제휴, 합병, 인수합병도 혁신과 파이프라인 확장을 가속화하고 있습니다. 또한, 주요 시장에서의 유리한 규제 프레임워크, 신속 승인 제도, 희귀질환 치료제 지정은 새로운 면역치료제의 신속한 상용화를 가능하게 하여 시장 성장에 크게 기여하고 있습니다.

종양학 분야 외에도 면역항암제 시장은 전 세계적으로 적용 범위가 확대되고 의료 인프라가 개선됨에 따라 전체 시장의 잠재력이 확대되고 있습니다. 자가면역질환, 감염성 질환, 희귀유전성 질환에 대한 면역치료 연구가 진행되어 임상 적용 범위가 확대되고 있습니다. 선진국의 경우, 강력한 상환 시스템, 높은 의료비 지출, 고급 진단 시설에 대한 접근성이 면역치료제의 일상적인 사용을 촉진했습니다. 한편, 신흥경제국에서는 헬스케어 시스템 개선, 의료관광 증가, 암 치료 체계 강화를 위한 정부 정책으로 인해 꾸준한 성장세를 보였습니다. 환자와 의료진의 인식 개선과 더불어 생물학적 제제의 비용 효율성이 점진적으로 개선되면서 보급이 더욱 확대되고 있습니다. 이러한 상호 연관된 요인들이 결합되어 세계 면역치료제 시장의 장기적인 성장 전망과 지속적인 혁신이 유지되고 있습니다.

자주 묻는 질문

  • 면역치료제 시장 규모는 어떻게 예측되나요?
  • 면역치료제 시장의 성장은 어떤 요인에 의해 주도되고 있나요?
  • 면역치료제 시장에서 기술 발전은 어떤 역할을 하고 있나요?
  • 면역치료제 시장의 주요 기업은 어디인가요?
  • 면역치료제 시장의 성장에 기여하는 규제 환경은 어떤가요?

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 면역치료제 시장 변수, 동향, 범위

제4장 면역치료제 시장 : 약제 유형별, 추정 및 동향 분석

제5장 면역치료제 시장 : 적응증별, 추정 및 동향 분석

제6장 면역치료제 시장 : 지역별, 추정 및 동향 분석

제7장 경쟁 구도

LSH 26.03.11

Immunotherapy Drugs Market Summary

The global immunotherapy drugs market size was estimated at USD 285.73 billion in 2025 and is expected to reach USD 675.98 billion by 2033, growing at a CAGR of 11.41% from 2026 to 2033. This market is primarily driven by the rising incidence of chronic diseases globally.

This market was driven by the rising global burden of cancer and chronic diseases, including autoimmune and inflammatory disorders, alongside the growing limitations of conventional treatments such as chemotherapy and radiation therapy. These constraints had accelerated the shift toward immunotherapy because of its targeted mechanism of action and improved patient outcomes. For instance, February 2025, the World Health Organization reported that cancer was responsible for nearly 10 million deaths in 2020, accounting for almost one in six deaths globally. Breast cancer recorded 2.26 million cases, lung cancer 2.21 million, and colorectal cancer 1.93 million, while lung cancer caused 1.80 million deaths. The organization also estimated around 400,000 childhood cancer cases annually and noted that 30 percent of cancers in low and lower middle income countries were infection related, reinforcing demand for advanced immunotherapies.

Technological advancements and robust research activity play a critical role in driving the immunotherapy drugs market forward. Significant progress in immuno-oncology, particularly in immune checkpoint inhibitors, monoclonal antibodies, and cell-based therapies such as CAR-T, has transformed cancer treatment paradigms. These therapies have demonstrated strong efficacy across multiple solid tumors and hematological malignancies, leading to expanding clinical indications. Pharmaceutical and biotechnology companies are investing heavily in research and development to improve therapeutic effectiveness, reduce adverse effects, and develop next-generation immunotherapies. Strategic collaborations, mergers, and acquisitions are also accelerating innovation and pipeline expansion. Moreover, favorable regulatory frameworks, fast-track approvals, and orphan drug designations in major markets are enabling faster commercialization of novel immunotherapy drugs, thereby contributing significantly to market growth.

Beyond oncology, the immunotherapy drugs market was supported by expanding applications and improving healthcare infrastructure worldwide, which broadened overall market potential. Immunotherapies were increasingly explored for autoimmune diseases, infectious diseases, and rare genetic disorders, enabling wider clinical adoption. In developed regions, strong reimbursement systems, higher healthcare spending, and access to advanced diagnostic facilities facilitated routine use of immunotherapy drugs. At the same time, emerging economies experienced steady growth due to improvements in healthcare systems, rising medical tourism, and government initiatives aimed at strengthening cancer care delivery. Growing awareness among patients and healthcare providers, coupled with gradual improvements in the affordability of biologic therapies, further supported uptake. Together, these interconnected factors sustained long term growth prospects and continued innovation in the global immunotherapy drugs market.

Global Immunotherapy Drugs Market Report Segmentation

This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this report, Grand View Research has segmented the global immunotherapy drugs market report based on drug type, indication, and region:

  • Drug Type Outlook (Revenue, USD Million, 2021 - 2033)
  • Monoclonal Antibodies
  • Immunomodulator
  • Vaccine
  • Others
  • Indication Outlook (Revenue, USD Million, 2021 - 2033)
  • Cancer
  • Autoimmune Diseases
  • Infectious Diseases
  • Others
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Thailand
    • South Korea
    • Australia
  • Latin America
    • Brazil
    • Argentina
  • Middle East and Africa (MEA)
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
    • 1.3.1. Information Procurement
    • 1.3.2. Information or Data Analysis
    • 1.3.3. Market Formulation & Data Visualization
    • 1.3.4. Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Immunotherapy Drugs Market Variables, Trends, & Scope

  • 3.1. Market Introduction/Lineage Outlook
  • 3.2. Market Size and Growth Prospects (USD Million)
  • 3.3. Market Dynamics
    • 3.3.1. Market Drivers Analysis
    • 3.3.2. Market Restraints Analysis
  • 3.4. Immunotherapy Drugs Market Analysis Tools
    • 3.4.1. Porter's Analysis
      • 3.4.1.1. Bargaining power of the suppliers
      • 3.4.1.2. Bargaining power of the buyers
      • 3.4.1.3. Threats of substitution
      • 3.4.1.4. Threats from new entrants
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Economic and Social landscape.
      • 3.4.2.3. Technological landscape
      • 3.4.2.4. Environmental landscape
      • 3.4.2.5. Legal landscape

Chapter 4. Immunotherapy Drugs Market: Drug Type Estimates & Trend Analysis

  • 4.1. Drug Type Market Share, 2025 & 2033
  • 4.2. Drug Type Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Drug Type, 2021 to 2033 (USD Million)
  • 4.4. Monoclonal Antibodies
    • 4.4.1. Monoclonal Antibodies Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.5. Immunomodulator
    • 4.5.1. Immunomodulator Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.6. Vaccine
    • 4.6.1. Vaccine Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.7. Others
    • 4.7.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Immunotherapy Drugs Market: Indication Estimates & Trend Analysis

  • 5.1. Indication Market Share, 2025 & 2033
  • 5.2. Indication Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Drug Type, 2021 to 2033 (USD Million)
  • 5.4. Cancer
    • 5.4.1. Cancer Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.5. Autoimmune Diseases
    • 5.5.1. Autoimmune Diseases Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.6. Infectious Diseases
    • 5.6.1. Infectious Diseases Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.7. Others
    • 5.7.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Immunotherapy Drugs Market: Regional Estimates & Trend Analysis

  • 6.1. Regional Market Share Analysis, 2025 & 2033
  • 6.2. Regional Market Dashboard
  • 6.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
  • 6.4. North America
    • 6.4.1. North America Immunotherapy Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.4.2. U.S.
      • 6.4.2.1. Key Country Dynamics
      • 6.4.2.2. Regulatory Framework
      • 6.4.2.3. Competitive Insights
      • 6.4.2.4. U.S. Immunotherapy Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.4.3. Canada
      • 6.4.3.1. Key Country Dynamics
      • 6.4.3.2. Regulatory Framework
      • 6.4.3.3. Competitive Insights
      • 6.4.3.4. Canada Immunotherapy Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.4.4. Mexico
      • 6.4.4.1. Key Country Dynamics
      • 6.4.4.2. Regulatory Framework
      • 6.4.4.3. Competitive Insights
      • 6.4.4.4. Mexico Immunotherapy Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5. Europe
    • 6.5.1. Europe Immunotherapy Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.2. UK
      • 6.5.2.1. Key Country Dynamics
      • 6.5.2.2. Regulatory Framework
      • 6.5.2.3. Competitive Insights
      • 6.5.2.4. UK Immunotherapy Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.3. Germany
      • 6.5.3.1. Key Country Dynamics
      • 6.5.3.2. Regulatory Framework
      • 6.5.3.3. Competitive Insights
      • 6.5.3.4. Germany Immunotherapy Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.4. France
      • 6.5.4.1. Key Country Dynamics
      • 6.5.4.2. Regulatory Framework
      • 6.5.4.3. Competitive Insights
      • 6.5.4.4. France Immunotherapy Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.5. Italy
      • 6.5.5.1. Key Country Dynamics
      • 6.5.5.2. Regulatory Framework
      • 6.5.5.3. Competitive Insights
      • 6.5.5.4. Italy Immunotherapy Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.6. Spain
      • 6.5.6.1. Key Country Dynamics
      • 6.5.6.2. Regulatory Framework
      • 6.5.6.3. Competitive Insights
      • 6.5.6.4. Spain Immunotherapy Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.7. Denmark
      • 6.5.7.1. Key Country Dynamics
      • 6.5.7.2. Regulatory Framework
      • 6.5.7.3. Competitive Insights
      • 6.5.7.4. Denmark Immunotherapy Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.8. Sweden
      • 6.5.8.1. Key Country Dynamics
      • 6.5.8.2. Regulatory Framework
      • 6.5.8.3. Competitive Insights
      • 6.5.8.4. Sweden Immunotherapy Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.9. Norway
      • 6.5.9.1. Key Country Dynamics
      • 6.5.9.2. Regulatory Framework
      • 6.5.9.3. Competitive Insights
      • 6.5.9.4. Norway Immunotherapy Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.6. Asia Pacific
    • 6.6.1. Asia Pacific Immunotherapy Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.2. Japan
      • 6.6.2.1. Key Country Dynamics
      • 6.6.2.2. Regulatory Framework
      • 6.6.2.3. Competitive Insights
      • 6.6.2.4. Japan Immunotherapy Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.3. China
      • 6.6.3.1. Key Country Dynamics
      • 6.6.3.2. Regulatory Framework
      • 6.6.3.3. Competitive Insights
      • 6.6.3.4. China Immunotherapy Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.4. India
      • 6.6.4.1. Key Country Dynamics
      • 6.6.4.2. Regulatory Framework
      • 6.6.4.3. Competitive Insights
      • 6.6.4.4. India Immunotherapy Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.5. Thailand
      • 6.6.5.1. Key Country Dynamics
      • 6.6.5.2. Regulatory Framework
      • 6.6.5.3. Competitive Insights
      • 6.6.5.4. Thailand Immunotherapy Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.6. South Korea
      • 6.6.6.1. Key Country Dynamics
      • 6.6.6.2. Regulatory Framework
      • 6.6.6.3. Competitive Insights
      • 6.6.6.4. South Korea Immunotherapy Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.7. Australia
      • 6.6.7.1. Key Country Dynamics
      • 6.6.7.2. Regulatory Framework
      • 6.6.7.3. Competitive Insights
      • 6.6.7.4. Australia Immunotherapy Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.7. Latin America
    • 6.7.1. Latin America Immunotherapy Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.7.2. Brazil
      • 6.7.2.1. Key Country Dynamics
      • 6.7.2.2. Regulatory Framework
      • 6.7.2.3. Competitive Insights
      • 6.7.2.4. Brazil Immunotherapy Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.7.3. Argentina
      • 6.7.3.1. Key Country Dynamics
      • 6.7.3.2. Regulatory Framework
      • 6.7.3.3. Competitive Insights
      • 6.7.3.4. Argentina Immunotherapy Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.8. Middle East and Africa
    • 6.8.1. Middle East and Africa Immunotherapy Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.8.2. South Africa
      • 6.8.2.1. Key Country Dynamics
      • 6.8.2.2. Regulatory Framework
      • 6.8.2.3. Competitive Insights
      • 6.8.2.4. South Africa Immunotherapy Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.8.3. Saudi Arabia
      • 6.8.3.1. Key Country Dynamics
      • 6.8.3.2. Regulatory Framework
      • 6.8.3.3. Competitive Insights
      • 6.8.3.4. Saudi Arabia Immunotherapy Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.8.4. UAE
      • 6.8.4.1. Key Country Dynamics
      • 6.8.4.2. Regulatory Framework
      • 6.8.4.3. Competitive Insights
      • 6.8.4.4. UAE Immunotherapy Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.8.5. Kuwait
      • 6.8.5.1. Key Country Dynamics
      • 6.8.5.2. Regulatory Framework
      • 6.8.5.3. Competitive Insights
      • 6.8.5.4. Kuwait Immunotherapy Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Participant Overview
  • 7.2. Company Market Position Analysis
  • 7.3. Company Categorization
  • 7.4. Strategy Mapping
  • 7.5. Company Profiles/Listing
    • 7.5.1. Amgen Inc.
      • 7.5.1.1. Participant's Overview
      • 7.5.1.2. Financial Performance
      • 7.5.1.3. Product Benchmarking
      • 7.5.1.4. Recent Developments/ Strategic Initiatives
    • 7.5.2. Novartis AG
      • 7.5.2.1. Participant's Overview
      • 7.5.2.2. Financial Performance
      • 7.5.2.3. Product Benchmarking
      • 7.5.2.4. Recent Developments/ Strategic Initiatives
    • 7.5.3. AbbVie Inc.
      • 7.5.3.1. Participant's Overview
      • 7.5.3.2. Financial Performance
      • 7.5.3.3. Product Benchmarking
      • 7.5.3.4. Recent Developments/ Strategic Initiatives
    • 7.5.4. Pfizer Inc.
      • 7.5.4.1. Participant's Overview
      • 7.5.4.2. Financial Performance
      • 7.5.4.3. Product Benchmarking
      • 7.5.4.4. Recent Developments/ Strategic Initiatives
    • 7.5.5. F. Hoffmann-La Roche Ltd
      • 7.5.5.1. Participant's Overview
      • 7.5.5.2. Financial Performance
      • 7.5.5.3. Product Benchmarking
      • 7.5.5.4. Recent Developments/ Strategic Initiatives
    • 7.5.6. Johnson & Johnson Services, Inc.
      • 7.5.6.1. Participant's Overview
      • 7.5.6.2. Financial Performance
      • 7.5.6.3. Product Benchmarking
      • 7.5.6.4. Recent Developments/ Strategic Initiatives
    • 7.5.7. AstraZeneca
      • 7.5.7.1. Participant's Overview
      • 7.5.7.2. Financial Performance
      • 7.5.7.3. Product Benchmarking
      • 7.5.7.4. Recent Developments/ Strategic Initiatives
    • 7.5.8. GSK plc.
      • 7.5.8.1. Participant's Overview
      • 7.5.8.2. Financial Performance
      • 7.5.8.3. Product Benchmarking
      • 7.5.8.4. Recent Developments/ Strategic Initiatives
    • 7.5.9. Sanofi
      • 7.5.9.1. Participant's Overview
      • 7.5.9.2. Financial Performance
      • 7.5.9.3. Product Benchmarking
      • 7.5.9.4. Recent Developments/ Strategic Initiatives
    • 7.5.10. Bayer AG
      • 7.5.10.1. Participant's Overview
      • 7.5.10.2. Financial Performance
      • 7.5.10.3. Product Benchmarking
      • 7.5.10.4. Recent Developments/ Strategic Initiatives
샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제